Abstract:Objective: As a member of the N-myc downregulated gene family, N-Myc downstream-regulated gene 2 (NDRG2) contributes to tumorigenesis of various types of cancer. The expression status of NDRG2 in colorectal cancer (CRC) and its prognostic value remain to be elucidated. The goal of this study was to determine the expression pattern of NDRG2 in human CRC and its association of NDRG2 expression with prognosis. Methods: Immunohistochemistry was used to determine the level of NDRG2 expressions in 316 CRC tissues. The medical records of consecutive CRC patients undergoing primary tumor resection from September 2000 to February 2015 were retrospectively selected. Then, we compared to specific clinicopathological features in patients with different level of NDRG2 expressions. The correlation of NDRG2 expression with 3-year survival rate was assessed by Kaplan-Meier method and Cox regression modeling. Results: NDRG2 was expressed in 94.6% (299/316) of CRC tissues. The median IHC score of NDRG2 expression was significantly lower in tumor tissues compared with that of tumor-adjacent normal tissues [4.50(range 0.00-12.00) vs. 10.00 (range 0.00-12.00), P < 0.001].Survival analysis indicated that patients with low NDRG2 expression had poorer 3-year OS than those with high NDRG2 expression (59.9% vs. 76.6%, P = 0.017). Low NDRG2 expression also presented a significantly poorer 3-year OS rate in patient with stage IV disease (29.4% vs. 56.5%, P = 0.002), liver metastasis(32.2% vs. 54.7%, P = 0.005) and those receiving liver resection(56.5% vs. 71.9% , P = 0.012). Multivariate analysis indicated that high NDRG2 expression was independently associated with poor OS (hazard ratio [HR]: 1.499; 95% confidence interval [CI]: 1.037-2.165; P = 0.031). Conclusions: Low expression of NDRG2 was associated with unfavorable prognosis in CRC patients with primary tumor resection. Detection of NDRG2 expression might be useful for providing valuable information of individualized therapy for CRC patients.

Overexpression of N-Myc Downstream-Regulated Gene 2 (NDRG2) Regulates the Proliferation and Invasion of Bladder Cancer Cells in Vitro and in Vivo

N-myc Downstream Regulated Gene 1 Inhibition of Tumor Progression in Caco2 Cells.

Lentivirus-mediated NDRG2 gene overexpression inhibits radioresistance of bladder cancer cells

Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer

NDRG2 increases bladder cancer cell sensitivity to cisplatin by inhibiting Bcl-2 expression

N-Myc Downstream-Regulated Gene 2 (NDRG2) As a Novel Tumor Suppressor in Multiple Human Cancers

Suppression of Invasion and Metastasis of Prostate Cancer Cells by Overexpression of NDRG2 Gene.

Expression of NDRG2 in Clear Cell Renal Cell Carcinoma.

N-Myc Downstream-Regulated Gene 2 (ndrg2) Inhibits Glioblastoma Cell Proliferation

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

Up-Regulation Of Pvhl Along With Down-Regulation Of Hif-L Alpha By Ndrg2 Expression Attenuates Proliferation And Invasion In Renal Cancer Cells

NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498

Expression of NDRG2 in Human Colorectal Cancer and its Association with Prognosis.

Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion

N-myc Downstream-Regulated Gene 2 Expression is Associated with Glucose Transport and Correlated with Prognosis in Breast Carcinoma

NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

Microarray profiling of HepG2 cells ectopically expressing NDRG2.

NDRG2 Down-Regulation and CD24 Up-Regulation Promote Tumor Aggravation and Poor Survival in Patients with Gallbladder Carcinoma

Suppression of N-Myc Downstream-Regulated Gene 2 is Associated with Induction of Myc in Colorectal Cancer and Correlates Closely with Differentiation

Tumor Suppressor NDRG 2 Tips the Balance of Oncogenic TGF-β Via EMT Inhibition in Colorectal Cancer